Siemens Healthineers has entered into a merger agreement with Corindus Vascular Robotics, a global technology leader in robotic- assisted vascular interventions, whereby Siemens will acquire Corindus for $1.1 billion Based in Waltham, MA, USA, Corindus produces and sells robotic systems for minimally invasive procedures. These systems help clinicians to precisely control guide catheters, guide wires, balloon or stent implants via integrated imaging. The physician no longer has to stand close by the angiography table as usual but can control the procedure with a separate module and is thus less exposed to radiation. Corindus is currently one of the leading companies offering a robotic treatment platform for major vascular therapeutic markets, including coronary, peripheral vascular and neurovascular interventions
Every year, more than four million percutaneous coronary interventions are carried out worldwide. Robotic-assisted minimally invasive procedures have the potential to reduce treatment times, increase precision during treatment, raise standardization levels in clinical procedures and ultimately improve clinical outcomes. The interplay of exact imaging and robotic-assisted interventions will thus enhance both the eyes and hands of the physician.
“With Corindus, Siemens Healthineers is well-positioned to be one of the leading players in the field of robotic vascular interventions and to perform minimally invasive procedures more accurately, more quickly and more effectively. With this acquisition, we are opening up a new field for our image-guided therapies business. Together with our strong portfolio in imaging, digitalization and artificial intelligence, we are creating significant synergies to advance therapy outcomes”, said Bernd Montag, CEO of Siemens Healthineers
The CorPath systems developed by Corindus will be used together with Siemens’ angiography systems which make minimally invasive treatment possible by using high-quality imaging before and during medical interventions. The company’s leading role in image-based minimally invasive procedures is now complemented by robotic-assisted precision medicine. This expansion strengthens the therapy position of Siemens Healthineers and underlines its role as one of the leading providers of solutions along the entire treatment path. This makes the acquisition of Corindus a strategically significant extension of Siemens Healthineers’ therapy business.
In addition, Corindus is driving forward the approval procedure for remote robotic treatment in vascular interventions. Due to the limited availability of specialists for minimally invasive procedures in many regions and the limited number of corresponding clinical facilities, remote treatment could significantly improve patients’ access to treatment in the future.